Page 1 | Search Results | Blood | American Society of Hematology

1-14 of 14

Sort by

Sort Order Select

Journal Articles

Outcomes after Transplant in Relapsed/Refractory KMT2Ar (MLLr) and mNPM1 (NPM1c) leukemia Patients Achieving Remissions after Menin Inhibition: SNDX-5613 (revumenib) Ph1 Experience

Blood (2022) 140 (Supplement 1): 914–916.

https://doi.org/10.1182/blood-2022-164600

Published: 2022

Journal Articles

Selective HDAC6 Inhibitor ACY-241, an Oral Tablet, Combined with Pomalidomide and Dexamethasone: Safety and Efficacy of Escalation and Expansion Cohorts in Patients with Relapsed or Relapsed-and-Refractory Multiple Myeloma (ACE-MM-200 Study)

Blood (2016) 128 (22): 3307.

https://doi.org/10.1182/blood.V128.22.3307.3307

Published: 2016

Journal Articles

Ricolinostat (ACY-1215), the First Selective HDAC6 Inhibitor, Combines Safely with Pomalidomide and Dexamethasone and Shows Promosing Early Results in Relapsed-and-Refractory Myeloma (ACE-MM-102 Study)

Noopur S. Raje, MD, William Bensinger, MD, Craig E. Cole, MD, Sagar Lonial, MD, Sundar Jagannath, MD, Carlos E. Arce-Lara, MD, Jason Valent, MD, Ashley E Rosko, MD, Wael A. Harb, MD, Irwindeep Sandhu, MD, Nizar J Bahlis, MD, Donna Reece, Evangelos Terpos, MD, Jeffrey Supko, PhD, David Tamang, PhD, Simon S Jones, PhD, Catherine Wheeler, MD, Robert J Markelewicz, Jr., MD, Paul G. Richardson

Blood (2015) 126 (23): 4228.

https://doi.org/10.1182/blood.V126.23.4228.4228

Published: 2015

Journal Articles

Ricolinostat (ACY-1215), the First Selective HDAC6 Inhibitor, in Combonation with Lenalidomide and Dexamethasone in Patients with Relapsed and Relapsed-and-Refractory Multiple Myeloma: Phase 1b Results (ACE-MM-101 Study)

Andrew J. Yee, MD, William Bensinger, MD, Peter M. Voorhees, MD, Jesus G. Berdeja, MD, Paul G. Richardson, MD, Jeffrey Supko, PhD, David Tamang, PhD, Simon S Jones, PhD, Catherine Wheeler, MD, Robert J Markelewicz, Jr., MD, Noopur S. Raje, MD

Blood (2015) 126 (23): 3055.

https://doi.org/10.1182/blood.V126.23.3055.3055

Published: 2015

Journal Articles

Ricolinostat (ACY-1215), the First Selective HDAC6 Inhibitor, in Combination with Bortezomib and Dexamethasone in Patients with Relapsed or Relapsed-and-Refractory Multiple Myeloma: Phase 1b Results (ACY-100 Study)

Dan T. Vogl, MD, Noopur S. Raje, MD, Sundar Jagannath, MD, Paul G. Richardson, MD, Parameswaran Hari, MD MRCP, MS, Robert Z. Orlowski, PhD, MD, Jeffrey Supko, PhD, David Tamang, PhD, Simon S Jones, PhD, Catherine Wheeler, MD, Robert J Markelewicz, Jr., MD, Sagar Lonial, MD

Blood (2015) 126 (23): 1827.

https://doi.org/10.1182/blood.V126.23.1827.1827

Published: 2015

Journal Articles

Phase 1B Results of Ricolinostat (ACY-1215) Combination Therapy with Bortezomib and Dexamethasone in Patients with Relapsed or Relapsed and Refractory Multiple Myeloma (MM)

Dan T. Vogl, Noopur Raje, MD, Parameswaran Hari, MBBS, MD MRCP, Simon S Jones, PhD, Jeffrey G Supko, PhD, Gina Leone, RN, Catherine Wheeler, MD, Robert Z. Orlowski, PhD MD, Paul G. Richardson, Sagar Lonial, MD, David Tamang, PhD, Sundar Jagannath, MD

Blood (2014) 124 (21): 4764.

https://doi.org/10.1182/blood.V124.21.4764.4764

Published: 2014

Journal Articles

Ricolinostat (ACY-1215), a Selective HDAC6 Inhibitor, in Combination with Lenalidomide and Dexamethasone: Results of a Phase 1b Trial in Relapsed and Relapsed Refractory Multiple Myeloma

Andrew J Yee, MD, Peter M. Voorhees, MD, William Bensinger, Jesus G. Berdeja, MD, Jeffrey G Supko, PhD, Paul G. Richardson, David Tamang, PhD, Simon S Jones, PhD, Gretchen Patrick, Catherine Wheeler, MD, Noopur Raje, MD

Blood (2014) 124 (21): 4772.

https://doi.org/10.1182/blood.V124.21.4772.4772

Published: 2014

Journal Articles

Inhibition Of HDAC6 In Combination With Targeted Agents Results In Broad Synergistic Decreases In Viability In Non-Hodgkin’s Lymphoma (NHL) Cells

Steven N Quayle, PhD, David Tamang, PhD, Min Yang, PhD, Simon S Jones, PhD

Blood (2013) 122 (21): 3071.

https://doi.org/10.1182/blood.V122.21.3071.3071

Published: 2013

Journal Articles

Preclinical Combination Of The Oral Investigational Agents ACY-1215, a Selective HDAC6 Inhibitor, and Ixazomib, a Proteasome Inhibitor, Demonstrates Combination Benefit In Multiple Myeloma Cell Lines and Xenograft Models

Allison J Berger, PhD, Bret Bannerman, Steven N Quayle, PhD, Jie Yu, Khristofer Garcia, Jeffrey Ciavarri, PhD, David Tamang, PhD, Min Yang, PhD, Simon S Jones, PhD

Blood (2013) 122 (21): 4437.

https://doi.org/10.1182/blood.V122.21.4437.4437

Published: 2013

Journal Articles

Discovery Histone Deacetylase (HDAC)6 Specific Proteomic Biomarkers In Multiple Myeloma (MM) Using Stable Isotope Labeling By Amino Acids In Cell Culture (SILAC)

Min Yang, PhD, David Tamang, PhD, Simon S Jones, PhD, Zhongyi Cheng, Ph.D., Gungwei Chirn, Ph.D

Blood (2013) 122 (21): 1909.

https://doi.org/10.1182/blood.V122.21.1909.1909

Published: 2013

Journal Articles

Tubulin Hyper-Acetylation In Blood Lymphocytes: Pharmacodynamic (PD) Biomarker For The Selective Histone Deacetylase (HDAC) 6 Inhibitor ACY-1215 In Multiple Myeloma (MM) Patients

David Tamang, PhD, Simon S Jones, PhD, Min Yang, PhD, Jeff Supko

Blood (2013) 122 (21): 3219.

https://doi.org/10.1182/blood.V122.21.3219.3219

Published: 2013

Journal Articles

Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma

Loredana Santo, Teru Hideshima, Andrew L. Kung, Jen-Chieh Tseng, David Tamang, Min Yang, Matthew Jarpe, John H. van Duzer, Ralph Mazitschek, Walter C. Ogier, Diana Cirstea, Scott Rodig, Homare Eda, Tyler Scullen, Miriam Canavese, James Bradner, Kenneth C. Anderson, Simon S. Jones, Noopur Raje

Blood (2012) 119 (11): 2579–2589.

https://doi.org/10.1182/blood-2011-10-387365

Published: 2012

Includes: Supplemental data

Journal Articles

Selective HDAC6 Inhibition Via ACY-1215, Either Alone or in Combination with Bortezomib, Restores Osteoblast Function and Suppresses Osteoclast Differentiation in Multiple Myeloma

Loredana Santo, MD, Teru Hideshima, MD, PhD, Andrew L. Kung, MD, PhD, Jen-Chieh Tseng, PhD, David Tamang, PhD, Min Yang, PhD, Matthew Jarpe, PhD, John H. van Duzer, PhD, Ralph Mazitschek, PhD, Diana Cirstea, MD, Homare Eda, MD, PhD, Tyler A. Scullen, BA, Scott Rodig, MD, PhD, Miriam Canavese, PhD, James Bradner, MD, Kenneth C Anderson, MD, Simon Jones, PhD, Noopur S. Raje, MD

Blood (2011) 118 (21): 2908.

https://doi.org/10.1182/blood.V118.21.2908.2908

Published: 2011

Journal Articles

Pharmacodynamic and Pharmacokinetic Properties of a Novel and Selective HDAC6 Inhibitor, ACY-1215, in Combination with Bortezomib in Multiple Myeloma

Loredana Santo, MD, Teru Hideshima, MD, PhD, Andrew L. Kung, MD, PhD, Jen-Chieh Tseng, PhD, David Tamang, PhD, Min Yang, PhD, Matthew Jarpe, PhD, John H. van Duzer, PhD, Ralph Mazitschek, PhD, Walter C Ogier, Diana D. Cirstea, MD, Scott Rodig, MD, PhD, Homare Eda, MD, PhD, Tyler A. Scullen, BA, Miriam Canavese, PhD, James E. Bradner, MD, Kenneth C Anderson, MD, Simon Jones, PhD, Noopur S. Raje, MD

Blood (2011) 118 (21): 2912.

https://doi.org/10.1182/blood.V118.21.2912.2912

Published: 2011

NARROW

Outcomes after Transplant in Relapsed/Refractory KMT2Ar (MLLr) and mNPM1 (NPM1c) leukemia Patients Achieving Remissions after Menin Inhibition: SNDX-5613 (revumenib) Ph1 Experience

Selective HDAC6 Inhibitor ACY-241, an Oral Tablet, Combined with Pomalidomide and Dexamethasone: Safety and Efficacy of Escalation and Expansion Cohorts in Patients with Relapsed or Relapsed-and-Refractory Multiple Myeloma (ACE-MM-200 Study)

Ricolinostat (ACY-1215), the First Selective HDAC6 Inhibitor, Combines Safely with Pomalidomide and Dexamethasone and Shows Promosing Early Results in Relapsed-and-Refractory Myeloma (ACE-MM-102 Study)

Ricolinostat (ACY-1215), the First Selective HDAC6 Inhibitor, in Combonation with Lenalidomide and Dexamethasone in Patients with Relapsed and Relapsed-and-Refractory Multiple Myeloma: Phase 1b Results (ACE-MM-101 Study)

Ricolinostat (ACY-1215), the First Selective HDAC6 Inhibitor, in Combination with Bortezomib and Dexamethasone in Patients with Relapsed or Relapsed-and-Refractory Multiple Myeloma: Phase 1b Results (ACY-100 Study)

Phase 1B Results of Ricolinostat (ACY-1215) Combination Therapy with Bortezomib and Dexamethasone in Patients with Relapsed or Relapsed and Refractory Multiple Myeloma (MM)

Ricolinostat (ACY-1215), a Selective HDAC6 Inhibitor, in Combination with Lenalidomide and Dexamethasone: Results of a Phase 1b Trial in Relapsed and Relapsed Refractory Multiple Myeloma

Inhibition Of HDAC6 In Combination With Targeted Agents Results In Broad Synergistic Decreases In Viability In Non-Hodgkin’s Lymphoma (NHL) Cells

Preclinical Combination Of The Oral Investigational Agents ACY-1215, a Selective HDAC6 Inhibitor, and Ixazomib, a Proteasome Inhibitor, Demonstrates Combination Benefit In Multiple Myeloma Cell Lines and Xenograft Models

Discovery Histone Deacetylase (HDAC)6 Specific Proteomic Biomarkers In Multiple Myeloma (MM) Using Stable Isotope Labeling By Amino Acids In Cell Culture (SILAC)

Tubulin Hyper-Acetylation In Blood Lymphocytes: Pharmacodynamic (PD) Biomarker For The Selective Histone Deacetylase (HDAC) 6 Inhibitor ACY-1215 In Multiple Myeloma (MM) Patients

Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma

Selective HDAC6 Inhibition Via ACY-1215, Either Alone or in Combination with Bortezomib, Restores Osteoblast Function and Suppresses Osteoclast Differentiation in Multiple Myeloma

Pharmacodynamic and Pharmacokinetic Properties of a Novel and Selective HDAC6 Inhibitor, ACY-1215, in Combination with Bortezomib in Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only